Question 1

What is the catalog number for APTX Knockout HT29 Polyclonal Cells?

Accepted Answer

The catalog number for APTX Knockout HT29 Polyclonal Cells is ARG33000.

Question 2

What sizes are available for APTX Knockout HT29 Polyclonal Cells?

Accepted Answer

APTX Knockout HT29 Polyclonal Cells is available in the following size(s): 1 Million.

Question 3

Is APTX Knockout HT29 Polyclonal Cells in stock?

Accepted Answer

APTX Knockout HT29 Polyclonal Cells is currently made to order / not held in immediate stock. Contact us for lead time.

Question 4

Are there any special shipping requirements for APTX Knockout HT29 Polyclonal Cells?

Accepted Answer

APTX Knockout HT29 Polyclonal Cells is requires dry ice shipping.

Question 5

How long will it take to receive this product if it’s custom made?

Accepted Answer

Lead times depend on the product type: custom polyclonal antibodies typically take 12-14 weeks, monoclonal antibodies 15-17 weeks, made-to-order recombinant proteins 4-8 weeks, and made-to-order recombinant antibodies 6-8 weeks. These are estimates and may shift due to production delays.

Question 6

What is the recommended dilution for this antibody?

Accepted Answer

A recommended dilution range for each validated application is provided on the datasheet, but optimal dilution should be titrated for your specific experimental system, sample type, and detection method.

Question 7

What is the recommended storage temperature after reconstitution?

Accepted Answer

Post-reconstitution storage guidance is listed on the datasheet, typically requiring aliquoting and storage at -20°C or -80°C to preserve activity.

APTX Knockout HT29 Polyclonal Cells

Product Specifications

Type

Shipping Conditions

Storage Conditions

Frequently Asked Questions

Explore Other Products

GIT1 Polyclonal Antibody

GIT1 Polyclonal Antibody

Lentiviral mouse Snrnp48 shRNA (UAS) - Lentiviral mouse Snrnp48 shRNA (UAS, GFP) plasmid

V6 Anti-Human CD20 (Ublituximab)

V6 Anti-Human CD20 (Ublituximab)

V6 Anti-Human CD20 (Ublituximab)